NEW YORK (GenomeWeb News) – Hologic said today that its proposed $580 million acquisition of Third Wave Technologies has received from the Federal Trade Commission early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
 
Hologic announced two weeks ago that it will acquire Third Wave Technologies for $11.25 per share, a 24 percent premium to Third Wave’s average trading price during the preceding three months. 
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.